首页> 美国卫生研究院文献>other >A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

【2h】

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

机译：Erlotinib与抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（Cixtutumumab）组合的I / II类研究在高级非小细胞肺癌患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

IntroductionThis phase I/II study evaluated the safety and anti-tumor effect of the combination of erlotinib with cixutumumab, a recombinant fully humanized anti-insulin-like growth factor-1 receptor IgG1 monoclonal antibody, in advanced non-small cell lung cancer (NSCLC).

著录项

期刊名称 other
作者
Andrew Weickhardt; Robert Doebele; Ana Oton; Janice Lettieri; DeLee Maxson; Michele Reynolds; Amy Brown; Mary K. Jackson; Grace Dy; Araba Adjei; Gerald Fetterly; Xian Lu; Wilbur Franklin; Marileila Varella-Garcia; Fred R. Hirsch; Murry W. Wynes; Hagop Youssoufian; Alex Adjei; D. Ross Camidge;
展开▼
作者单位

展开▼
年(卷),期 -1(7),2
年度 -1
页码 419–426
总页数 15
原文格式 PDF
正文语种
中图分类
关键词
Non-small cell lung cancer IGF1R monoclonal antibody EGFR Metastatic disease;

机译：非小细胞肺癌;IGF1R单克隆抗体;EGFR;转移性疾病;

相似文献

外文文献
中文文献
专利

1. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. [J] . Weickhardt A, Doebele R, Oton A, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第2期

机译：欧尔替尼与抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（Cixtutumumab）组合的抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（Cixutumumab）的阶段I / II研究。
2. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. [J] . Weickhardt A, Doebele R, Oton A, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第2期

机译：欧尔替尼与抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（Cixtutumumab）组合的抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（Cixutumumab）的阶段I / II研究。
3. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. [J] . Weickhardt A, Doebele R, Oton A, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第2期

机译：厄洛替尼与抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（西妥昔单抗）联合用于晚期非小细胞肺癌患者的I / II期研究。
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507 a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor for Advanced-Stage Non–Small-Cell Lung Cancer [O] . Suresh S. Ramalingam, David R. Spigel, David Chen, -1

机译：厄洛替尼联合安慰剂或R1507（胰岛素样生长因子-1受体单克隆抗体）用于晚期非小细胞肺癌的随机II期研究
7. A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer [O] . Weickhardt Andrew, Doebele Robert, Oton Ana, 2012

机译：厄洛替尼与抗胰岛素样生长因子-1受体单克隆抗体IMC-A12（西妥珠单抗）联合用于晚期非小细胞肺癌患者的I / II期研究

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅